Logo

People in the News: Paul Kinnon

Oct 02, 2013
Premium

Transgenomic has appointed Paul Kinnon to president and CEO, replacing Craig Tuttle. Kinnon will also serve as a director on the company's board. He previously provided commercial and strategic consultancy services to Transgenomics and other life science companies. He was also CEO of ZyGem and previously held positions at Invitrogen, Guava Technologies, and Cellomics.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Precipio
Next-Generation Sequencing
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.